
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6252324/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer, 2007, 110, 2083-2091.	2.0	197
2	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
3	Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 161, 83-94.	1.1	156
4	Behavioral Interventions to Increase Adherence in Colorectal Cancer Screening. Medical Care, 1991, 29, 1039-1050.	1.1	139
5	Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Research and Treatment, 2015, 154, 563-571.	1.1	124
6	Biopsychosocial Aspects of Prostate Cancer. Psychosomatics, 2000, 41, 85-94.	2.5	106
7	Adherence to colorectal cancer screening in an HMO population. Preventive Medicine, 1990, 19, 502-514.	1.6	93
8	Factorial Validity and Invariance of a Survey Measuring Psychosocial Correlates of Colorectal Cancer Screening among African Americans and Caucasians. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2855-2861.	1.1	92
9	Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology, 2016, 150, 1135-1146.	0.6	92
10	Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia. Cancer, 1996, 78, 471-479.	2.0	91
11	Interventions to improve follow-up of abnormal findings in cancer screening. Cancer, 2004, 101, 1188-1200.	2.0	90
12	Adherence by African American men to prostate cancer education and early detection. , 1999, 86, 88-104.		82
13	Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Preventive Medicine, 2004, 38, 375-381.	1.6	81
14	Gender differences in attitudes impeding colorectal cancer screening. BMC Public Health, 2013, 13, 500.	1.2	79
15	Genetic Polymorphisms in Pre-microRNA Genes as Prognostic Markers of Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 217-227.	1.1	74
16	Tailored Navigation in Colorectal Cancer Screening. Medical Care, 2008, 46, S123-S131.	1.1	73
17	Decision counseling in cancer prevention and control Health Psychology, 2005, 24, S71-S77.	1.3	69
18	Family Factors in End-of-Life Decision-Making: Family Conflict and Proxy Relationship. Journal of Palliative Medicine, 2011, 14, 179-184.	0.6	68

#	Article	IF	CITATIONS
19	Comprehensive Analysis of Common Serum Liver Enzymes as Prospective Predictors of Hepatocellular Carcinoma in HBV Patients. PLoS ONE, 2012, 7, e47687.	1.1	67
20	Automated Telephone Calls Improved Completion of Fecal Occult Blood Testing. Medical Care, 2010, 48, 604-610.	1.1	66
21	A Randomized Controlled Trial of a Tailored Navigation and a Standard Intervention in Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 109-117.	1.1	66
22	Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Scientific Reports, 2016, 6, 23992.	1.6	66
23	Adherence to Continuous Screening for Colorectal Neoplasia. Medical Care, 1993, 31, 508-519.	1.1	65
24	Physician-reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. American Journal of Gastroenterology, 2003, 98, 2078-2081.	0.2	65
25	Receptivity of african-american men to prostate cancer screening. Urology, 1994, 43, 480-487.	0.5	64
26	Intention to Screen for Colorectal Cancer among White Male Employees. Preventive Medicine, 1998, 27, 279-287.	1.6	61
27	Depression in Korean Immigrants With Hepatitis B and Related Liver Diseases. Psychosomatics, 2000, 41, 472-480.	2.5	56
28	Increasing Colon Cancer Screening in Primary Care Among African Americans. Journal of the National Cancer Institute, 2014, 106, dju344-dju344.	3.0	56
29	Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. Journal of General Internal Medicine, 2003, 18, 357-363.	1.3	53
30	Correlates and Predictors of Colorectal Cancer Screening among Male Automotive Workers. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 500-509.	1.1	53
31	Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. European Journal of Cancer, 2012, 48, 1014-1022.	1.3	52
32	A survey of women regarding factors affecting colorectal cancer screening compliance. Preventive Medicine, 2004, 38, 669-675.	1.6	49
33	Preoperative Platelet Count Associates with Survival and Distant Metastasis in Surgically Resected Colorectal Cancer Patients. Journal of Gastrointestinal Cancer, 2013, 44, 293-304.	0.6	49
34	Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening. Journal of the National Medical Association, 2005, 97, 1143-54.	0.6	49
35	Costâ€effectiveness of targeted and tailored interventions on colorectal cancer screening use. Cancer, 2008, 112, 779-788.	2.0	48
36	Personal Navigation Increases Colorectal Cancer Screening Uptake. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 506-511.	1.1	47

#	Article	IF	CITATIONS
37	Consultations for â€~Maladaptive Denial of Illness' in Patients with Cancer: Psychiatric Disorders that Result in Noncompliance. , 1997, 6, 139-149.		46
38	Reasons Patients With a Positive Fecal Occult Blood Test Result Do Not Undergo Complete Diagnostic Evaluation. Annals of Family Medicine, 2009, 7, 11-16.	0.9	46
39	The Case for Patient Navigation in Lung Cancer Screening in Vulnerable Populations: A Systematic Review. Population Health Management, 2019, 22, 347-361.	0.8	42
40	What is a good medical decision? A research agenda guided by perspectives from multiple stakeholders. Journal of Behavioral Medicine, 2017, 40, 52-68.	1.1	40
41	Mediated decision support in prostate cancer screening: A randomized controlled trial of decision counseling. Patient Education and Counseling, 2011, 83, 240-246.	1.0	39
42	Examining the Role of Perceived Susceptibility on Colorectal Cancer Screening Intention and Behavior. Annals of Behavioral Medicine, 2010, 40, 205-217.	1.7	38
43	GWAS-identified colorectal cancer susceptibility locus associates with disease prognosis. European Journal of Cancer, 2011, 47, 1699-1707.	1.3	38
44	Costâ€effectiveness of a standard intervention versus a navigated intervention on colorectal cancer screening use in primary care. Cancer, 2014, 120, 1042-1049.	2.0	37
45	African-American men and intention to adhere to recommended follow-up for an abnormal prostate cancer early detection examination result. Urology, 2000, 55, 716-720.	0.5	36
46	Genetic and Environmental Risk Assessment and Colorectal Cancer Screening in an Average-Risk Population. Annals of Internal Medicine, 2014, 161, 537.	2.0	35
47	Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. European Journal of Cancer, 2019, 106, 133-143.	1.3	35
48	Potentially functional genetic variants in <i>KDR</i> gene as prognostic markers in patients with resected colorectal cancer. Cancer Science, 2012, 103, 561-568.	1.7	31
49	Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis <scp>B</scp> virus infection. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 131-138.	1.4	31
50	Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast Cancer Research and Treatment, 2020, 181, 679-689.	1.1	30
51	Intention to be screened over time for colorectal cancer in male automotive workers. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 339-49.	1.1	30
52	Complete Diagnostic Evaluation in Colorectal Cancer Screening: Research Design and Baseline Findings. Preventive Medicine, 2001, 33, 249-260.	1.6	29
53	Measuring Informed Decision Making about Prostate Cancer Screening in Primary Care. Medical Decision Making, 2012, 32, 327-336.	1.2	28
54	Obesity and Cancer Screening according to Race and Gender. Journal of Obesity, 2011, 2011, 1-10.	1.1	26

#	Article	IF	CITATIONS
55	Telephone-Based Shared Decision-making for Lung Cancer Screening in Primary Care. Journal of Cancer Education, 2020, 35, 766-773.	0.6	24
56	Decision counseling for men considering prostate cancer screening. Computers and Operations Research, 2003, 30, 1421-1434.	2.4	23
57	Decision Support and Navigation to Increase Colorectal Cancer Screening Among Hispanic Patients. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 384-391.	1.1	22
58	The effect of HEDIS measurement of colorectal cancer screening on insurance plans in Pennsylvania. American Journal of Managed Care, 2008, 14, 277-82.	0.8	22
59	Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection – Results from a clinic-based longitudinal cohort. European Journal of Cancer, 2012, 48, 2319-2327.	1.3	21
60	Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer, 2013, 13, 340.	1.1	21
61	Telomere length in circulating serum <scp>DNA</scp> as a novel nonâ€invasive biomarker for cirrhosis: a nested case–control analysis. Liver International, 2012, 32, 1233-1241.	1.9	20
62	Cross-Cultural Validation of the Preventive Health Model for Colorectal Cancer Screening: An Australian Study. Health Education and Behavior, 2010, 37, 724-736.	1.3	18
63	Factors associated with colorectal cancer screening decision stage. Preventive Medicine, 2010, 51, 329-331.	1.6	18
64	A qualitative evaluation of strategies to increase colorectal cancer screening uptake. Canadian Family Physician, 2011, 57, e7-15.	0.1	18
65	Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 268.	1.7	16
66	Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. Cancer Causes and Control, 2015, 26, 45-56.	0.8	15
67	Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. Npj Breast Cancer, 2021, 7, 72.	2.3	15
68	Circulating Mitochondrial DNA Content Associated with the Risk of Liver Cirrhosis: A Nested Case–Control Study. Digestive Diseases and Sciences, 2015, 60, 1707-1715.	1.1	14
69	Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. Journal of Cancer Education, 2018, 33, 180-185.	0.6	14
70	Genetic Polymorphism in a VEGF-Independent Angiogenesis Gene ANGPT1 and Overall Survival of Colorectal Cancer Patients after Surgical Resection. PLoS ONE, 2012, 7, e34758.	1.1	14
71	Behaviors Used by Men to Protect Themselves against Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 78-86.	1.1	12
72	Race and response to colon cancer screening interventions. Preventive Medicine, 2011, 52, 262-4.	1.6	12

#	Article	IF	CITATIONS
73	Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. International Journal of Cancer, 2015, 136, 382-391.	2.3	12
74	The Effects of Test Preference, Test Access, and Navigation on Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1521-1528.	1.1	11
75	Predictors of overall and test-specific colorectal Cancer screening adherence. Preventive Medicine, 2020, 133, 106022.	1.6	11
76	Primary Care Colorectal Cancer Screening Recommendation Patterns. Medical Decision Making, 2012, 32, 198-208.	1.2	10
77	Predictors of patient uptake of colorectal cancer gene environment risk assessment. Genome Medicine, 2012, 4, 92.	3.6	10
78	Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1469-1475.	1.4	10
79	Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence. Clinical Lung Cancer, 2021, 22, 570-578.	1.1	10
80	Effects of genetic and environmental risk assessment feedback on colorectal cancer screening adherence. Journal of Behavioral Medicine, 2015, 38, 777-786.	1.1	9
81	Using a health system learning community strategy to address cancer disparities. Learning Health Systems, 2018, 2, e10067.	1.1	9
82	Factors Associated with Breast Cancer Screening Decision Stage among Women in Tehran, Iran. International Journal of Preventive Medicine, 2014, 5, 196-202.	0.2	9
83	Outreach to primary care patients in lung cancer screening: A randomized controlled trial. Preventive Medicine, 2022, 159, 107069.	1.6	9
84	A randomized trial of genetic and environmental risk assessment (GERA) for colorectal cancer risk in primary care: Trial design and baseline findings. Contemporary Clinical Trials, 2011, 32, 25-31.	0.8	8
85	Variation in Colorectal Cancer Screening Steps in Primary Care. American Journal of Medical Quality, 2012, 27, 458-466.	0.2	8
86	Genetic and environmental risk assessment for colorectal cancer risk in primary care practice settings: a pilot study. Genetics in Medicine, 2007, 9, 378-384.	1.1	7
87	A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients. BMC Cancer, 2016, 16, 766.	1.1	6
88	Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis, 2017, 38, 439-446.	1.3	6
89	Analysis of Colorectal Cancer Stage Among HMO Members Targeted for Screening. Archives of Internal Medicine, 1997, 157, 2001.	4.3	5
90	Genetic Variations in Stem Cell-Related Genes and Colorectal Cancer Prognosis. Journal of Gastrointestinal Cancer, 2012, 43, 584-593.	0.6	5

#	Article	IF	CITATIONS
91	Primary Care Physician Perceptions of Shared Decision Making in Lung Cancer Screening. Journal of Cancer Education, 2020, , 1.	0.6	5
92	Race/Ethnicity, Gender, Weight Status, and Colorectal Cancer Screening. Journal of Obesity, 2011, 2011, 1-6.	1.1	4
93	Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials. Preventive Medicine, 2017, 101, 229-234.	1.6	4
94	Health Organizations Have an Opportunity to Improve Shared Decision-Making and Raise Lung Cancer Screening Rates. Chest, 2021, 159, 23-24.	0.4	4
95	Effectiveness of complete diagnostic examination in clinical practice settings. Cancer Detection and Prevention, 2006, 30, 545-551.	2.1	3
96	Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment. Journal of Personalized Medicine, 2021, 11, 998.	1.1	3
97	A stepped randomized trial to promote colorectal cancer screening in a nationwide sample of U.S. Veterans. Contemporary Clinical Trials, 2021, 105, 106392.	0.8	2
98	Preparing African American Women for Breast Biopsy. Cancer Control, 2005, 12, 100-102.	0.7	1
99	Increasing access to clinical and educational studies. Cancer, 2006, 107, 1962-1970.	2.0	1
100	Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. Breast Cancer Research and Treatment, 2014, 148, 175-185.	1.1	1
101	The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study. Breast Cancer Research and Treatment, 2015, 153, 407-416.	1.1	1
102	Community Physician Willingness to Refer Cancer Patients for Tkeatment Education. Annals of the New York Academy of Sciences, 1995, 768, 323-326.	1.8	0
103	Low rates of diagnostic colonoscopy in Federally Qualified Health Centers: A persistent problem that must be addressed to achieve the promise of colorectal cancer screening. Cancer, 2019, 125, 4134-4135.	2.0	Ο